Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy

靶向 MTF2-MDM2 轴可增强难治性急性髓系白血病对化疗的敏感性

阅读：7

作者：Harinad B Maganti #, Hani Jrade #, Christopher Cafariello, Janet L Manias Rothberg, Christopher J Porter, Julien Yockell-Lelièvre, Hannah L Battaion, Safwat T Khan, Joel P Howard, Yuefeng Li, Adrian T Grzybowski, Elham Sabri, Alexander J Ruthenburg, F Jeffrey Dilworth, Theodore J Perkins, Mitchell S

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2018

起止号：

2018 Nov;8(11):1376-1389.

doi：

10.1158/2159-8290.CD-17-0841

研究方向：

肿瘤

疾病类型：

白血病

Significance

MTF2 deficiency predicts refractory AML at diagnosis. MTF2 represses MDM2 in hematopoietic cells and its loss in AML results in chemoresistance. Inhibiting p53 degradation by overexpressing MTF2 in vitro or by using MDM2 inhibitors in vivo sensitizes MTF2-deficient refractory AML cells to a standard induction-chemotherapy regimen. Cancer Discov; 8(11); 1376-89. ©2018 AACR. See related commentary by Duy and Melnick, p. 1348 This article is highlighted in the In This Issue feature, p. 1333.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。